

E.11 Antiviral drugs (IV acyclovir or oral valganciclovir) versus placebo

Figure 125: Fatigue: Multidimensional fatigue inventory (MFI-20) at 9 months (oral)




Figure 126: Fatigue: POMS fatigue at 37 days (IV)




Figure 127: Fatigue: POMS vigour at 37 days (IV)




Figure 128: Psychological status: POMS anxiety at 37 days (IV)




Figure 129: Psychological status: POMS depression at 37 days (IV)




Figure 130: Psychological status: POMS anger at 37 days (IV)




Figure 131: Psychological status: POMS confusion at 37 days (IV)




Figure 132: Adverse events: treatment-related adverse events (oral)




Figure 133: Adverse events: reversible renal failure (IV)




Figure 134: Activity levels: rest (hours/day) at 37 days (IV)




Figure 135: Symptom scales: Wellness score at 37 days (IV)

